

Correlation between choline containing metabolites and choline kinase in untreated pediatric brain tumors

D. E. Schofield¹, A. Panigrahy², M. D. Krieger³, M. D. Nelson², F. H. Gilles⁴, I. Gonzalez-Gomez⁴, S. Bluml^{2,5}

¹Pathology, Childrens Hospital Los Angeles, Los Angeles, CA, United States, ²Radiology, Childrens Hospital Los Angeles, Los Angeles, CA, United States, ³Neurosurgery, Childrens Hospital Los Angeles, Los Angeles, CA, United States, ⁴Neuropathology, Childrens Hospital Los Angeles, Los Angeles, CA, United States, ⁵Rudi Schulte Reserach Institute, Santa Barbara, CA, United States

Introduction: Childhood neuroglial tumors of the same diagnostic name or grade contain histologic subsets that differ markedly in survival expectation (1,2). Generally, in cell lines and in animal models of cancer, elevated intracellular phosphocholine (PC) pools and an increased PC to glycerophosphocholine (PC/GPC) ratio have been associated with increased malignancy (3-7). Also elevated choline kinase (CHK) activity, facilitating the synthesis of PC from free choline, and a possible cause for large PC pools, has been associated with increased malignancy (8,9). The goal of this study was to characterize the relationship between CHK expression and total choline (tCho), PC/GPC, and PC/ATP in pediatric brain tumors.

Methods: Untreated tumors from eight children (4 medulloblastoma, 2 ependymoma, 1 astrocytoma, 1 fibrous histiocytoma) were studied with *in vivo* ¹H and proton-decoupled ³¹P MRS. Short echo time (TE=35ms) single voxel ¹H spectra were acquired using a PRESS sequence and metabolite concentration were quantified in mmol/kg tissue using LCModel (10). Slice selective chemical shift imaging (6 × 6 phase encoding steps) with a self-refocusing RF pulse was used for ³¹P acquisitions and spectra were processed as described in detail in Ref. (11). Patients underwent brain surgery within 3 days of MRS studies. Tissue samples were analyzed with the Affymetrix (Santa Clara, CA) human genome U133 Plus 2.0 chip. Frozen tumor specimen were cut and reviewed with the microscope. Samples with a fraction of > 90% of tumor cells were chosen. Total RNA was extracted and processed following the manufacturer recommended procedures.

Results: PC was prominent whereas GPC was hardly detectable in medulloblastoma and PC/GPC was thus not evaluated (Fig. 1). PC/ATP (GPC/ATP) was significantly higher (lower) in medulloblastoma when compared with other tumors. tCho was not significantly different in this small group of patients. When all data were pooled a positive correlation was found between PC/ATP and the CHK expression index whereas there was no correlation between CHK and tCho (Fig. 2). The mean CHK expression index was 70% higher in medulloblastoma than in other tumors but did not reach significance due to considerable variations in individual tumors.

Discussion: Choline containing compounds are involved in the synthesis and breakdown of phosphatidylcholine (PtdCho). PtdCho is the major phospholipid component of eukaryotic cells accounting for approx. 60% of total phospholipids. Rapid synthesis of PtdCho is a feature of fast growing tumors. The data indicate that *in vivo* PC/ATP rather than tCho may be useful as an *in vivo* surrogate marker for CHK activity. This is unfortunate because ¹H MRS is readily available on clinical MR systems whereas proton-decoupled ³¹P MRS is time consuming and requires special hardware. The identification of surrogate *in vivo* markers could be important for monitoring of the efficiency of anticancer drugs that specifically aim to inhibit choline kinase (12).

Acknowledgment: This work was supported by grant 5R33-CA096032-04 (National Cancer Institute).

References: 1. Brown WD et al. J Neuropathol Exp Neurol 1998;57(11):1035-1040. 2. Gilles F et al. Pediatric and Developmental Pathology 2000;3:126-139. 3. Aboagye EO, Bhujwala ZM. Cancer Res 1999;59(1):80-84. 4. Ackerstaff E et al. J Cell Biochem 2003;90(3):525-533. 5. Podo F. NMR Biomed 1999;12(7):413-439. 6. Daly PF et al. J Biol Chem 1987;262:14875-14878. 7. Radda GK et al. Ann NY Acad Sci 1987;508:300-308. 8. Katz-Brull R, Degani H. Anticancer Res 1996;16(3B):1375-1380. 9. Ramirez de Molina A, et al. Oncogene 2002;21(27):4317-4322. 10. Provencher SW. Magn Reson Med 1993;30(6):672-679. 11. Albers MJ et al. Magn Reson Med 2005;53(1):22-29. 12. Lacal JC. IDrugs 2001;4(4):419-426.




Fig. 1: Proton-decoupled ³¹P MRS, ¹H MRS, and MRI of cerebellar medulloblastoma (A+B) and ependymoma (C). ³¹P spectra are scaled to ATP as an internal reference. ¹H spectra are scaled to measured absolute concentrations to allow direct comparison with each other. Areas or amplitudes of ³¹P and ¹H spectra can not be directly compared. All spectra were acquired on a clinical 1.5 T scanner. A custom-designed dual tuned head coil was used for clinically indicated MR imaging, proton MRS, and for experimental ³¹P MRS. The total examination time was approximately 70 min. ROIs for ¹H (small box) and ³¹P are marked on MRI, respectively.




Fig. 2: Correlation between choline containing compounds measured *in vivo* pre-operatively with proton-decoupled ³¹P MRS and ¹H MRS and the choline kinase expression index. Solid circles = medulloblastoma.